Quick Answer
ANAPTYSBIO, INC reported Net Income Loss of -$13.23 million for the year ending 2025.
- ANAPTYSBIO, INC showed an increase of +90.9% in Net Income Loss from 2024 to 2025.
- This data is from ANAPTYSBIO, INC's annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: -$888.0 thousand | Q2 2016: $2.32 million | Q3 2016: -$1.12 million | Q1 2017: -$11.44 million | Q2 2017: -$2.68 million | Q3 2017: -$9.09 million | Q1 2018: -$15.09 million | Q2 2018: -$13.62 million | Q3 2018: -$15.96 million | Q1 2019: -$22.08 million | Q2 2019: -$23.96 million | Q3 2019: -$31.03 million | Q1 2020: -$8.26 million | Q2 2020: -$21.55 million | Q3 2020: -$23.77 million | Q1 2021: -$18.16 million | Q2 2021: -$429.0 thousand | Q3 2021: -$6.67 million | Q1 2022: -$36.26 million | Q2 2022: -$32.55 million | Q3 2022: -$33.50 million | Q1 2023: -$44.26 million | Q2 2023: -$39.85 million | Q3 2023: -$37.31 million | Q1 2024: -$43.94 million | Q2 2024: -$46.66 million | Q3 2024: -$32.85 million | Q1 2025: -$39.33 million | Q2 2025: -$38.63 million | Q3 2025: $15.11 million.
- Over the full 11 years of available data (2015 to 2025), ANAPTYSBIO, INC's Net Income Loss has declined by 144.8%.
- Historical annual values: Fiscal year 2025: -$13.23 million | Fiscal year 2024: -$145.23 million | Fiscal year 2023: -$163.62 million | Fiscal year 2022: -$128.72 million | Fiscal year 2021: -$57.80 million | Fiscal year 2020: -$19.93 million | Fiscal year 2019: -$97.34 million | Fiscal year 2018: -$61.66 million | Fiscal year 2017: -$30.07 million | Fiscal year 2016: -$4.26 million | Fiscal year 2015: -$5.41 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: